INT241780

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.12
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 4
Disease Relevance 2.41
Pain Relevance 0.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transmembrane transport (AVP) cell-cell signaling (AVP) response to stress (AVP)
signal transducer activity (AVP) cytosol (AVP) extracellular space (AVP)
Anatomy Link Frequency
reticulum 1
AVP (Homo sapiens)
TRGV9 (Homo sapiens)
Pain Link Frequency Relevance Heat
medulla 4 94.24 High High
antagonist 84 89.20 High High
fibrosis 4 85.60 High High
headache 4 81.12 Quite High
adenocard 4 69.60 Quite High
Pain 8 27.36 Quite Low
anticonvulsant 8 23.80 Low Low
tricyclic antidepressant 8 23.12 Low Low
Nicotine 4 21.04 Low Low
Morphine 4 20.64 Low Low
Disease Link Frequency Relevance Heat
Pressure And Volume Under Development 36 99.32 Very High Very High Very High
Nephrogenic Diabetes Insipidus 12 93.72 High High
Hyponatremia 248 93.16 High High
Congenital Anomalies 4 88.08 High High
Internal Fibrosis 4 85.60 High High
Cyst 8 84.52 Quite High
Headache 4 81.12 Quite High
Polycystic Kidney Disease 24 80.96 Quite High
Fever 4 78.80 Quite High
Constipation 4 78.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
AVP: V2 interaction and water homeostasis
AVP Binding (interaction) of V2
1) Confidence 0.12 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504060 Disease Relevance 0.16 Pain Relevance 0.08
It was suggested that the agent acts as a pharmacologic chaperone to improve trafficking of the mutated misfolded V2 receptors to the cell surface where they can interact with AVP to enhance free water retention (Bernier et al 2006).
AVP Binding (interact) of V2 associated with pressure and volume under development
2) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504060 Disease Relevance 1.01 Pain Relevance 0.14
The pathogenic mechanisms may involve mutations leading to reduced AVP binding to V2 receptors (type 1), misfolding hence reduced trafficking of V2 receptors from the endoplasmic reticulum to cell surface (type 2), or direct defect in the transcription of V2 receptors (type 3) (Fujiwara and Bichet 2005).
AVP Binding (binding) of V2 in reticulum
3) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504060 Disease Relevance 0.75 Pain Relevance 0.13
The physiological effects of AVP are currently known to depend on its interaction with any of 3 receptor subtypes V1A, V2, and V1B.
AVP Binding (interaction) of V2
4) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Abstract Doc Link PMC2504060 Disease Relevance 0.49 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox